TherapeuticsMD Inc (TXMD) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
TherapeuticsMD Inc stock (TXMD) is currently trading at $2.29. TherapeuticsMD Inc PE ratio is 229.00. TherapeuticsMD Inc PS ratio (Price-to-Sales) is 9.48. Analyst consensus price target for TXMD is $5.00. WallStSmart rates TXMD as Sell.
- TXMD PE ratio analysis and historical PE chart
- TXMD PS ratio (Price-to-Sales) history and trend
- TXMD intrinsic value — DCF, Graham Number, EPV models
- TXMD stock price prediction 2025 2026 2027 2028 2029 2030
- TXMD fair value vs current price
- TXMD insider transactions and insider buying
- Is TXMD undervalued or overvalued?
- TherapeuticsMD Inc financial analysis — revenue, earnings, cash flow
- TXMD Piotroski F-Score and Altman Z-Score
- TXMD analyst price target and Smart Rating
TherapeuticsMD Inc
📊 No data available
Try selecting a different time range
TXMD Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · TherapeuticsMD Inc (TXMD)
TXMD trades 3357% above its Graham fair value of $0.07, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
TherapeuticsMD Inc (TXMD) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and peg ratio. Mixed signals suggest waiting for clearer direction before acting.
TherapeuticsMD Inc (TXMD) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 43.30% year-over-year
Supporting Valuation Data
TherapeuticsMD Inc (TXMD) Areas to Watch (7)
PEG ratio is negative or unavailable
Losing money on operations
Very low returns on shareholder equity
Very expensive at 9.5x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Decent profitability, keeps $11 per $100 revenue
Supporting Valuation Data
TherapeuticsMD Inc (TXMD) Detailed Analysis Report
Overall Assessment
This company scores 37/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 2 register as strengths (avg 10.0/10) while 7 fall into concern territory (avg 2.3/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.95) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 43.30%.
The Bear Case
The primary concerns are PEG Ratio, Operating Margin, Return on Equity. Some valuation metrics including PEG Ratio (N/A), Price/Sales (9.48) suggest expensive pricing. Profitability pressure is visible in Return on Equity at 0.27%, Operating Margin at -37.80%, Profit Margin at 10.80%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 0.27% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 43.30% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
TXMD Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
TXMD's Price-to-Sales ratio of 9.48x sits near its historical average of 9.25x (86th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 9.48x set in Mar 2026, and 6% above its historical low of 8.94x in Mar 2026.
Compare TXMD with Competitors
Top DRUG MANUFACTURERS - SPECIALTY & GENERIC stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for TherapeuticsMD Inc (TXMD) · HEALTHCARE › DRUG MANUFACTURERS - SPECIALTY & GENERIC
The Big Picture
TherapeuticsMD Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 3M with 43% growth year-over-year. Profit margins of 10.8% are healthy, with room for further expansion as the business scales.
Key Findings
Revenue growing at 43% YoY, reaching 3M. This pace significantly outperforms most DRUG MANUFACTURERS - SPECIALTY & GENERIC peers.
Generating 1M in free cash flow and 1M in operating cash flow. Earnings are translating into actual cash generation.
ROE of 0.3% suggests the company isn't efficiently converting equity into profits.
What to Watch Next
Margin expansion: can TherapeuticsMD Inc push profit margins above 15% as the business scales?
Growth sustainability: can TherapeuticsMD Inc maintain 43%+ revenue growth, or will competition slow it down?
Valuation compression risk at a P/E of 229.0x. Any growth miss could trigger a sharp correction.
Sector dynamics: monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive moves, and regulatory changes that could impact TherapeuticsMD Inc.
Bottom Line
TherapeuticsMD Inc offers an attractive blend of growth (43% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(0 last 3 months)
Data sourced from SEC Form 4 filings
Last updated: 10:05:33 AM
About TherapeuticsMD Inc(TXMD)
NASDAQ
HEALTHCARE
DRUG MANUFACTURERS - SPECIALTY...
USA
TherapeuticsMD, Inc. is a women's healthcare company in the United States. The company is headquartered in Boca Raton, Florida.